Publications by authors named "U Pleyer"

Background: Adalimumab, an anti-TNF-α biologic agent, has emerged as a principal treatment option for patients with non-infectious uveitis. The influence of adalimumab anti-drug antibodies (AAA) on the efficacy of adalimumab therapy is not yet fully understood. We aim to understand their clinical implications in the context of therapeutic drug monitoring and the factors contributing to the formation of these antibodies.

View Article and Find Full Text PDF

Background: Allogeneic graft rejection is the leading cause of graft failure in corneal transplantation (CT) despite the immune privilege of the anterior chamber and corneal bed. The ability to identify patients at higher risk of acute rejection before or after CT could have a major impact on the clinical management of these patients.

Methods: To address this important issue, a multicenter European cohort of low-risk (n = 142) and high-risk (n = 102) CT recipients was established, and the immune system was evaluated in detail in peripheral blood mononuclear cells and plasma before and 6 and 12 mo posttransplantation.

View Article and Find Full Text PDF
Article Synopsis
  • Tocilizumab (TCZ) is a drug used for rheumatic diseases that has shown promise in treating refractory non-infectious uveitis (NIU), particularly in Birdshot NIU, and this study examined its long-term effects.
  • Eight patients were monitored over an average of 33 months using various imaging techniques to assess retinal and choroidal inflammation, with significant improvements noted in retinal inflammation and central retinal thickness (CRT) after six months.
  • While TCZ effectively reduced retinal vasculitis and improved CRT, it was less effective for choroidal inflammation, indicating a need for further research to optimize TCZ treatment in NIU patients.
View Article and Find Full Text PDF
Article Synopsis
  • Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe, drug-induced skin conditions that can be life-threatening and are now viewed as different levels of the same disease known as epidermal necrolysis (EN).
  • A new guideline has been created based on scientific literature and expert consensus to help medical professionals in diagnosing and treating EN.
  • This guideline targets various specialists like dermatologists and intensive care doctors, as well as informing patients, families, insurers, and policymakers about EN and includes recommendations for acute care and follow-up treatment.
View Article and Find Full Text PDF